Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Characterizing RNA Therapeutic Stability for Global Regulatory Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Characterizing RNA Therapeutic Stability for Global Regulatory Submissions

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in CMC and Analytical Programs for RNA Therapeutics.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Executive Summary

A robust stability program is foundational to the successful clinical translation and regulatory approval of RNA therapeutics. For payloads such as mRNA, siRNA, or gRNA delivered via lipid nanoparticles (LNPs), stability is a complex interplay between payload integrity, delivery vehicle structure, and biological function. A phase-appropriate, data-driven stability program minimizes clinical risk by providing definitive evidence of product quality, consistency, and shelf-life, directly supporting accelerated 18-24 month IND timelines.

Frequently Asked Questions

How do stability programs for RNA therapeutics, particularly LNP-delivered mRNA, differ from those for viral vectors?

Stability programs for LNP-delivered RNA focus on a distinct set of quality attributes. While viral vectors require assessment of capsid integrity and genome titer, LNP systems demand rigorous characterization of particle size, polydispersity index (PDI), zeta potential, and RNA encapsulation efficiency. The inherent chemical lability of the RNA payload also necessitates specific assays for integrity and purity that differ from the DNA payloads of viral vectors.

What are the key stability-indicating assays required for an IMPD or IND submission for an saRNA therapeutic?

For an saRNA therapeutic, regulators expect a matrix of stability-indicating assays. This includes methods to confirm the identity and integrity of the full-length saRNA construct, quantification of purity (e.g., CGE), measurement of LNP encapsulation efficiency, and characterization of particle attributes. A qualified, cell-based potency assay demonstrating consistent biological activity over time is a required component to link physical stability to functional performance.

How does an early-stage stability program de-risk later-phase CMC development for next-generation therapies?

Initiating a formal stability program early establishes a baseline understanding of the molecule’s degradation pathways. This data informs formulation development, selection of container closure systems, and definition of shipping and handling procedures. Identifying potential liabilities before pivotal studies prevents costly delays and ensures the manufacturing process developed for early clinical phases is scalable and robust enough for commercialization.

Defining Stability for Complex RNA-LNP Formulations

The characterization of RNA therapeutics requires a multi-parametric approach. The stability profile is contingent not only on the RNA payload itself but also on the composition and structural integrity of the lipid nanoparticle delivery system. A comprehensive program evaluates how key quality attributes perform over time under various storage conditions, including long-term, accelerated, and stress testing scenarios as defined by ICH guidelines.

Key analytical assessments within these programs include:

  • Payload Integrity and Identity: Confirmation that the RNA sequence remains intact and free from degradation or modification.

  • LNP Physical Characteristics: Monitoring of particle size, polydispersity, and zeta potential, which directly influence biodistribution and cellular uptake.

  • Encapsulation and Purity: Quantifying the percentage of RNA successfully encapsulated within the LNP and assessing for process-related impurities.

  • Biological Potency: Utilizing qualified in vitro assays to confirm that the therapeutic retains its intended biological function throughout its shelf life.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Foundational Genetic and Structural Analysis

Lessons from adjacent modalities inform best practices for RNA. The development of rapid, accurate sequencing methods for viral vector plasmids (PMID: 30051733) underscores a foundational principle: the genetic identity of the therapeutic starting material must be unequivocally verified. For an mRNA or gRNA therapeutic, any sequence variation introduced during manufacturing or storage represents a direct failure of product identity. Our stability programs integrate next-generation sequencing to provide definitive confirmation of the payload sequence at key timepoints.

Similarly, work in mapping viral vector epitopes to understand immune interactions (PMID: 30089698) highlights the importance of structural characterization. For an LNP, the particle’s structure is its delivery interface with the biological system. Subtle changes in lipid composition or particle morphology due to storage conditions can significantly alter functional outcomes, meaning stability is defined by both the payload and the delivery vehicle.

GxP-Compliant Infrastructure for Global Submissions

Executing these complex, long-term studies requires significant infrastructure. Our >100,000 sq ft of dedicated laboratory and vivarium space provides the environmentally controlled and monitored GxP conditions necessary for generating submission-ready stability data. A virtual tour of these facilities is available here:.

This operational capacity, combined with the deep regulatory experience of our core scientific team, enables the design of stability protocols that meet global standards. This approach has been central to the 100% successful IND rate achieved by our principal scientists and study directors since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024. By generating a single, comprehensive data package, we support parallel submissions to multiple regulatory bodies, including the FDA and MHRA. These stability programs are a core component of our broader Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities